This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After Plunging -69.58% in 4 Weeks, Here's Why the Trend Might Reverse for CARGO Therapeutics, Inc. (CRGX)
by Zacks Equity Research
CARGO Therapeutics, Inc. (CRGX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why CARGO Therapeutics, Inc. (CRGX) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for CARGO Therapeutics, Inc. (CRGX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CARGO Therapeutics, Inc. (CRGX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CARGO Therapeutics, Inc. (CRGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -14.13% in 4 Weeks, Here's Why CARGO Therapeutics, Inc. (CRGX) Looks Ripe for a Turnaround
by Zacks Equity Research
CARGO Therapeutics, Inc. (CRGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bears are Losing Control Over CARGO Therapeutics, Inc. (CRGX), Here's Why It's a 'Buy' Now
by Zacks Equity Research
CARGO Therapeutics, Inc. (CRGX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
by Zacks Equity Research
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Company News for Mar 25, 2024
by Zacks Equity Research
Companies in The News Are:FDX,AIR,WS,CRGX
Alexandria (ARE) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Alexandria's (ARE) Q4 earnings are likely to have benefited from the healthy demand for its high-quality life science and lab office properties, high-interest expenses and economic uncertainty raise concern.
Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand
by Zacks Equity Research
Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses in Greater Boston and San Carlos in the San Francisco Bay Area.